Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aim: An injury sustained during sports activity can lead to the development of reinjury anxiety and hamper performance. Although tools exist to assess re-injury anxiety, a domain of interest in the field of sports medicine, research in the psychological impact of an orofacial injury is rudimentary. The present study envisaged to develop an instrument to assess the presence of reinjury anxiety following orofacial and dental injury in boxers aged between 10 and 16 years.
Methods: In Phase 1, items were generated following literature search and focus-group discussions (FGD). In Phase 2, a group discussion was conducted with three experienced boxing coaches to assess face validity, followed by two rounds of scrutiny by expert groups to assess the content validity through the content-validity-index (CVI), respectively. In Phase 3, the modified tool was pre-tested on an independent sample of young boxers. Finally, in Phase 4, to determine dimensionality, the modified tool was administered to 183 young boxers and their responses were subject to an exploratory factor analysis through Principal component analysis, followed by Promax rotation to determine the factor loading. Internal consistency reliability was measured through calculation of Cronbach's-alpha.
Results: From the 29-items devised initially, the tool was sequentially modified. Analysis of the responses by the second expert group, an average Scale-level-CVI of 0.9 and Universal agreement of 0.526 was obtained, which resulted in the inclusion of 20 items for the final phase of the study. From the factor analysis, the items were found to fit to a five-factor structure, which explained 56.4% of the variance in the constructs. Internal consistency of the tool was measured to be 0.74.
Conclusion: A 10-item oral re-injury anxiety scale for young boxers (ORAS-YB) tool was developed. It was found to have high face and content validity, and acceptable reliability. Further research with a larger sample is required to confirm the factor structure and determine test-retest reliability of the developed tool.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/edt.13039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease.
JAMA Neurol
August 2025
Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego.
Importance: Developing disease-modifying treatments is a priority for Alzheimer disease research.
Objective: To determine the potential of plasma phosphorylated tau 217 (p-tau217) and tau positron emission tomography (PET) to assess disease modification in treatment trials.
Design, Setting, And Participants: This diagnostic/prognostic study used longitudinal data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study collected from April 2014 to June 2023.
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.
Lancet Gastroenterol Hepatol
October 2025
Department of Medicine, University of Western Ontario, ON, Canada; Alimentiv, London, ON, Canada.
Background: TNF-like ligand 1A (TL1A) is an emerging therapeutic target for inflammatory bowel disease. We evaluated the safety and efficacy of multiple doses of afimkibart, a TL1A-directed antibody, in patients with moderately-to-severely active ulcerative colitis.
Methods: The multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b, TUSCANY-2 trial was conducted at 114 centres in 23 countries across North America, Europe, Asia, Africa, Australia, and South America.
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.
Lancet
July 2025
Dr Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:
Background: Despite the availability of biological therapies, suboptimal disease control remains a problem for patients with Crohn's disease. We report the results of the GALAXI-2 and GALAXI-3 studies, which aimed to assess the efficacy and safety of intravenous induction followed by subcutaneous maintenance therapy with guselkumab over 48 weeks in adults with moderately to severely active Crohn's disease.
Methods: GALAXI-2 and GALAXI-3 were identically designed, phase 3, randomised, double-blind, triple-dummy, treat-through trials with active and placebo comparators.
Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies known and novel cross-population and ancestry-specific associations as novel risk loci for Alzheimer's disease.
Genome Biol
July 2025
Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Background: Limited ancestral diversity has impaired our ability to detect risk variants more prevalent in ancestry groups of predominantly non-European ancestral background in genome-wide association studies (GWAS). We construct and analyze a multi-ancestry GWAS dataset in the Alzheimer's Disease Genetics Consortium (ADGC) to test for novel shared and population-specific late-onset Alzheimer's disease (LOAD) susceptibility loci and evaluate underlying genetic architecture in 37,382 non-Hispanic White (NHW), 6728 African American, 8899 Hispanic (HIS), and 3232 East Asian individuals, performing within ancestry fixed-effects meta-analysis followed by a cross-ancestry random-effects meta-analysis.
Results: We identify 13 loci with cross-population associations including known loci at/near CR1, BIN1, TREM2, CD2AP, PTK2B, CLU, SHARPIN, MS4A6A, PICALM, ABCA7, APOE, and two novel loci not previously reported at 11p12 (LRRC4C) and 12q24.
Effects of Selective Head-and-Neck Cooling on Brain Injury-Related Biomarker Levels and Symptom Rating Following a Boxing Bout: Protocol for an Exploratory Randomized Trial.
JMIR Res Protoc
June 2025
Department of Clinical Sciences Lund, Neurosurgery, Lund University, Skåne University Hospital, Lund, Sweden.
Background: Head impacts are common in contact sports such as boxing and occur at times of elevated core body and brain temperatures induced by the exercise. Following impact, elevated brain temperature may lead to the development of exacerbated brain injury that can be monitored by blood biomarkers. Blood-brain biomarkers S100B and glial fibrillary acidic protein (GFAP) reflect glial injury; neurofilament light (NFL), axonal injury; and Neuron-Specific Enolase (NSE) and Tubulin-associated unit (tau), neuronal injury.
View Article and Find Full Text PDF